Sanofi Adr Stock Debt To Equity
SNY Stock | USD 48.35 0.07 0.14% |
Sanofi ADR fundamentals help investors to digest information that contributes to Sanofi ADR's financial success or failures. It also enables traders to predict the movement of Sanofi Stock. The fundamental analysis module provides a way to measure Sanofi ADR's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sanofi ADR stock.
Last Reported | Projected for Next Year | ||
Debt To Equity | 0.22 | 0.18 |
Sanofi | Debt To Equity |
Sanofi ADR Company Debt To Equity Analysis
Sanofi ADR's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Sanofi ADR Debt To Equity | 0.30 % |
Most of Sanofi ADR's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sanofi ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Sanofi Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Sanofi ADR is extremely important. It helps to project a fair market value of Sanofi Stock properly, considering its historical fundamentals such as Debt To Equity. Since Sanofi ADR's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sanofi ADR's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sanofi ADR's interrelated accounts and indicators.
Click cells to compare fundamentals
Sanofi Debt To Equity Historical Pattern
Today, most investors in Sanofi ADR Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Sanofi ADR's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's debt to equity growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Sanofi ADR debt to equity as a starting point in their analysis.
Sanofi ADR Debt To Equity |
Timeline |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Competition |
Sanofi Total Stockholder Equity
Total Stockholder Equity |
|
According to the company disclosure, Sanofi ADR has a Debt To Equity of 0.297%. This is 99.45% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The debt to equity for all United States stocks is 99.39% higher than that of the company.
Sanofi Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sanofi ADR's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sanofi ADR could also be used in its relative valuation, which is a method of valuing Sanofi ADR by comparing valuation metrics of similar companies.Sanofi ADR is currently under evaluation in debt to equity category among its peers.
Sanofi ADR ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sanofi ADR's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sanofi ADR's managers, analysts, and investors.Environmental | Governance | Social |
Sanofi Fundamentals
Return On Equity | 0.0582 | ||||
Return On Asset | 0.0416 | ||||
Profit Margin | 0.09 % | ||||
Operating Margin | 0.29 % | ||||
Current Valuation | 140.02 B | ||||
Shares Outstanding | 2.51 B | ||||
Shares Owned By Institutions | 11.64 % | ||||
Number Of Shares Shorted | 8.12 M | ||||
Price To Earning | 7.78 X | ||||
Price To Book | 1.59 X | ||||
Price To Sales | 2.50 X | ||||
Revenue | 46.03 B | ||||
Gross Profit | 31.7 B | ||||
EBITDA | 12.6 B | ||||
Net Income | 5.4 B | ||||
Cash And Equivalents | 6.9 B | ||||
Cash Per Share | 2.76 X | ||||
Total Debt | 18.42 B | ||||
Debt To Equity | 0.30 % | ||||
Current Ratio | 1.30 X | ||||
Book Value Per Share | 58.10 X | ||||
Cash Flow From Operations | 10.26 B | ||||
Short Ratio | 4.07 X | ||||
Earnings Per Share | 1.88 X | ||||
Price To Earnings To Growth | 0.76 X | ||||
Target Price | 63.49 | ||||
Number Of Employees | 86.09 K | ||||
Beta | 0.45 | ||||
Market Capitalization | 121.05 B | ||||
Total Asset | 126.46 B | ||||
Retained Earnings | 67.5 B | ||||
Working Capital | 6.46 B | ||||
Current Asset | 24.93 B | ||||
Current Liabilities | 16.82 B | ||||
Annual Yield | 0.04 % | ||||
Five Year Return | 3.85 % | ||||
Net Asset | 126.46 B |
About Sanofi ADR Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sanofi ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sanofi ADR using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sanofi ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Sanofi Stock Analysis
When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.